FDA.reportPublic FDA data

nadofaragene firadenovec-vncg 300000000000 VIRAL-PARTICLES per 20 ML Intravesical Suspension

RxCUI
2644440
RxNorm name
nadofaragene firadenovec-vncg 300000000000 VIRAL-PARTICLES per 20 ML Intravesical Suspension
Display name
nadofaragene firadenovec-vncg 300000000000 VIRAL-PARTICLES per 20 ML Intravesical Suspension
Full name
nadofaragene firadenovec-vncg 300000000000 VIRAL-PARTICLES per 20 ML Intravesical Suspension
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:00

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125700Adstiladrinnadofaragene firadenovec-vncg351(a)Rx2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ADSTILADRINNADOFARAGENE FIRADENOVEC-VNCGFerring Pharmaceuticals Inc.5ca20ed4-da4f-463c-ac2a-ccd6ab3774fa2026-03-24Warnings, Adverse reactionsExact identifier
rxcui: 2644440

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
5ca20ed4-da4f-463c-ac2a-ccd6ab3774fanadofaragene firadenovec-vncg 300000000000 VIRAL-PARTICLES in 20 ML Intravesical Suspension [PSN] · nadofaragene firadenovec-vncg 15000000000 VIRAL-PARTICLES/ML Intravesical Suspension [SCD] · nadofaragene firadenovec-vncg 300000000000 VIRAL-PARTICLES per 20 ML Intravesical Suspension [SY]315These highlights do not include all the information needed to use ADSTILADRIN ® safely and effectively. See full prescribing information for ADSTILADRIN. ADSTILADRIN ® (nadofaragene firadenovec-vncg) suspension, for intravesical use Initial U.S. Approval: 202220260324